Reviving a human being after cryopreservation is not possible today, and no credible scientific timeline exists for when it might be. But the question is more nuanced than a simple yes or no. Several of the individual technologies required for revival have made real progress in the last decade, while other barriers remain enormous and unsolved. Here’s where things actually stand.
Cryonics vs. Cryogenics: A Quick Distinction
Most people searching this question mean cryonics, the practice of preserving human bodies at extremely low temperatures after legal death, hoping future technology can revive them. Cryogenics is the broader physics of producing and working with very cold temperatures. The two get mixed up constantly, but the speculative, sci-fi question is really about cryonics.
The core logic of cryonics rests on a chain of assumptions: low temperatures can virtually stop chemical changes for centuries; ice formation in tissues can be reduced or eliminated through a process called vitrification; legal death is not the same as irreversible death; and damage that can’t be repaired today may be repairable in the future. Each link in that chain has some scientific basis, but “some basis” is very different from “proven.”
What We Can Already Freeze and Revive
Cryopreservation works well at the cellular level. Human egg cells (oocytes) survive thawing about 79% of the time worldwide, and embryos created from frozen eggs result in live births roughly 35% of the time per transfer. For women who freeze eggs before age 35, the cumulative chance of a live birth can reach 75% with enough stored eggs. Sperm, blood cells, and skin tissue are routinely frozen and recovered. These successes prove that individual human cells can survive the process.
The problem is scale. A single cell is a few thousandths of a millimeter across. A human kidney is roughly 12 centimeters long and contains over a million tiny filtering units, each with its own blood supply. A brain contains roughly 86 billion neurons connected by trillions of synapses. Preserving a few cells in a droplet of fluid and preserving an entire organ with complex internal architecture are fundamentally different engineering challenges.
The Ice Problem and Vitrification
When tissue freezes slowly, water inside and between cells forms ice crystals that act like microscopic knives, shredding cell membranes and destroying structure. This is why you can’t freeze a strawberry and thaw it back to its original texture.
Vitrification avoids this by replacing much of the water in tissue with concentrated chemical protectants (cryoprotectants), then cooling so rapidly that the liquid solidifies into a glass-like state without forming crystals at all. This approach is considered the most promising path toward organ-level cryopreservation because it eliminates ice injury entirely during the freezing step. It’s already standard practice for freezing human eggs and embryos.
The catch is that cryoprotectants are toxic at the high concentrations needed to vitrify large tissues. Getting enough protectant into every cell of a whole organ without poisoning the tissue is one of the field’s central unsolved problems. Some newer research uses nanoparticles to deliver protective sugars like trehalose directly inside cells, and certain nanoparticles (like graphene oxide) can physically attach to ice crystals to restrict their growth. These are promising lab techniques, not clinical solutions yet.
The Rewarming Breakthrough
Even if you vitrify an organ perfectly, you can destroy it on the way back up. Rewarming too slowly lets ice crystals form after all. Rewarming unevenly creates thermal stress that cracks the tissue like a hot glass under cold water. For decades, this rewarming problem was arguably the biggest technical barrier.
A 2023 study published in Nature Communications offered the most dramatic proof of progress so far. Researchers vitrified rat kidneys, stored them for up to 100 days at minus 150°C, then rewarmed them using a technique called “nanowarming.” Tiny iron oxide nanoparticles were perfused throughout the organ’s blood vessels along with cryoprotectants. When placed inside a radiofrequency coil, the nanoparticles heated the entire organ from within at about 72°C per minute, fast enough and uniform enough to prevent both ice formation and cracking. The nanoparticles were then flushed out.
The rewarmed kidneys were transplanted into rats whose own kidneys had been removed. The transplanted organs restored full life-sustaining kidney function. Imaging confirmed no signs of ice crystallization or cracking. This is the first time a vitrified mammalian organ has been stored long-term, rewarmed, transplanted, and kept an animal alive.
Critically, the nanowarming approach should scale to larger organs because the radiofrequency fields penetrate tissue without weakening, and the nanoparticles are distributed through capillaries regardless of organ size. Whether it will work in human-sized organs hasn’t been demonstrated yet, but the physics suggests it could.
The Brain Is a Different Challenge
For people interested in cryonics specifically, the real question isn’t whether kidneys can be preserved. It’s whether the brain’s information content, the precise wiring pattern of neurons and synapses that encodes memory and identity, can survive the process.
A technique called aldehyde-stabilized cryopreservation (ASC) has shown that brain tissue can be chemically fixed and then vitrified with excellent structural preservation. When researchers examined ASC-processed brains under electron microscopy, neural processes were easily traceable and synapses appeared crisp across whole brains in multiple species. This was a brain-banking technique, not a revival method, but it demonstrated that the physical architecture encoding a brain’s connections can be preserved in vitrified tissue at a resolution fine enough for connectomics research.
Preserving structure and restoring function are not the same thing. Chemical fixation, by design, cross-links proteins in place. It’s like embalming at the molecular level. No one has proposed a viable method for reversing that fixation and restarting biological activity. The unfixed vitrification approach used in cryonics organizations avoids this problem but achieves less consistent structural preservation, especially in larger brains with longer perfusion times.
The Gap Between Preservation and Revival
This is where the honest assessment gets uncomfortable for cryonics advocates. Even the most optimistic reading of current science leaves multiple unsolved problems stacked on top of each other:
- Whole-body vitrification quality. No human body has been vitrified with confirmed, uniform glass formation throughout all tissues. Current cryonics procedures achieve partial vitrification at best, particularly in the brain’s deeper structures.
- Ischemic damage before preservation. Cryonics procedures can only legally begin after a person is declared dead. Alcor recommends starting within one to two minutes after the heart stops, and preferably within 15 minutes. In practice, delays of hours or more are common, during which cells degrade from oxygen deprivation. That damage accumulates before preservation even begins.
- Cryoprotectant toxicity. The chemicals that prevent ice also damage cells. Reducing this toxicity while maintaining protection is an active area of research with no complete solution.
- Repair technology doesn’t exist. Revival would require not just thawing but repairing all accumulated damage: from the dying process, from ischemia, from cryoprotectant toxicity, and from any imperfections in cooling or storage. The hypothetical technology to do this, often described as molecular-scale nanotechnology capable of cell-by-cell repair, is entirely theoretical.
Each of these problems is individually daunting. Solving all of them, and integrating those solutions into a single procedure that restores a functioning human being, represents a challenge of a completely different magnitude than anything accomplished so far.
Who Is Doing This Now
Several organizations offer cryopreservation services today. Alcor Life Extension Foundation charges $200,000 for whole-body preservation. The Cryonics Institute charges $28,000. Tomorrow Bio, a European provider, charges $220,000 for whole-body or $80,000 for preservation of the head only (neuro-preservation), plus $55 per month. International options like KrioRus in Russia or Yinfeng in China range from $50,000 to $100,000. Most members fund their preservation through life insurance policies.
These organizations operate on membership dues and donations rather than large-scale investment. Annual membership fees of $120 to $500 generate a combined $2.5 to $3 million per year across major providers. The relatively small financial base reflects the niche status of cryonics: a few thousand paying members worldwide, with a few hundred people currently in cryopreservation.
Legal Complications
Cryonics exists in an awkward legal space. The process can only begin after legal death is declared, which in most jurisdictions means either irreversible cessation of heartbeat or loss of brainstem function. This creates an inherent tension: the procedure works best when started immediately, but legal formalities can introduce delays. If a death is unexpected or occurs under circumstances that require investigation, a coroner may take temporary possession of the body and potentially require an autopsy, adding hours or days of warm ischemia that degrades the very tissues cryonics aims to preserve.
There is also no legal framework in any country that treats cryopreserved individuals as anything other than deceased. They are regulated under laws governing the disposal of the dead, not the treatment of patients. This means cryonics organizations have no legal obligation to maintain preservation indefinitely, and a preserved person has no legal rights.
A Realistic Assessment
The honest answer to “will cryonics ever work” depends on which version of “work” you mean. Preserving whole human organs for transplant banking, vitrifying them for months or years and rewarming them for use, looks increasingly plausible within the next few decades given the rat kidney results. That alone would transform organ donation.
Reviving a whole human being from cryopreservation is a categorically harder problem. It requires not just preserving and rewarming tissue but repairing extensive cellular damage across every organ system simultaneously, and doing so well enough to restore consciousness and identity. No existing or near-term technology can do this, and the theoretical frameworks proposed (molecular nanotechnology, advanced AI-guided repair) remain speculative. The gap between “we can rewarm a rat kidney” and “we can revive a cryopreserved human” is not a gap that incremental progress will close quickly. It may require entirely new fields of science that don’t yet exist.
For people currently in cryopreservation, the more pressing question may be whether the organizations storing them will remain solvent and functional for the decades or centuries needed. The financial model is fragile, the legal protections are minimal, and the technical requirements for eventual revival grow more demanding with every hour of ischemic damage that preceded their preservation.